Trident Lifeline Ltd (543616)
Latest quarterly results (Q1 FY27)
In its latest reported quarter, Q1 FY27, Trident Lifeline's revenue was ₹33.7 Cr (+42.8% year on year, -55.6% on the previous quarter), and net profit ₹5.1 Cr (+82.2% year on year); the operating margin was 25.3%.
| Q1 FY27 (₹ Cr) | Value | YoY vs Q1 FY26 | QoQ |
|---|---|---|---|
| Revenue | ₹33.7 | +42.8% | -55.6% |
| Operating profit | ₹8.5 | +64.7% | -46.8% |
| Net profit | ₹5.1 | +82.2% | -53.9% |
| EPS (₹) | 4.27 | +60.5% | -53.8% |
| Operating margin | 25.3% | — | — |
📢 Recent Corporate Announcements
Trident Lifeline Limited has issued a corrigendum to its October 27, 2026 EGM notice after receiving observations from the BSE during its in-principle approval application. The proposed preferential issue entails offering up to 12,22,200 equity shares at an issue price of Rs 336.60 per share (including Rs 326.60 premium), aggregating to Rs 41.14 crore. The corrigendum rectifies Ultimate Beneficial Owner (UBO) details for proposed allottee Fincos Technology Solutions and incorporates regulatory disclosures under SEBI ICDR regulations. The fundraise represents approximately 11.3% of the company's current market capitalization of Rs 363 crore and 41.5% of net worth.
- Proposed preferential issue of up to 12,22,200 equity shares aggregating to Rs 41,13,92,520 (Rs 41.14 crore)
- Issue price set at Rs 336.60 per share, which includes a face value of Rs 10 and a premium of Rs 326.60
- EGM to seek shareholder approval scheduled for October 27, 2026 via video conferencing
- Relevant date fixed as September 25, 2026 (30 days prior to the EGM date)
- Corrigendum rectifies inadvertent errors in UBO disclosure for Fincos Technology Solutions Private Limited per BSE observations
Trident Lifeline's board approved issuing a corrigendum to its EGM notice regarding the preferential issue of 12,22,200 equity shares and 5,00,400 warrants, following instructions from the stock exchange. The filing clarifies the objects of the issue, detailing proposed fund deployment across equity (₹41.14 Cr) and warrants (₹16.84 Cr), totaling ₹57.98 Cr. Proceeds are earmarked primarily for investments in subsidiaries/JVs (₹28.99 Cr total), working capital (₹14.50 Cr total), and general corporate expansion over a 24-month horizon. The total proposed capital raise represents ~16% of the company's current market capitalization of ₹363 Cr.
- Preferential allotment covers 12,22,200 equity shares and 5,00,400 warrants.
- Equity proceeds of ₹4113.93 Lacs (₹41.14 Cr) allocated to subsidiary investments (₹20.57 Cr), working capital (₹10.29 Cr), and expansion (₹10.28 Cr).
- Warrant proceeds of ₹1684.35 Lacs (₹16.84 Cr) allocated to subsidiary investments (₹8.42 Cr), working capital (₹4.21 Cr), and expansion (₹4.21 Cr).
- Proposed utilization timeline is within 24 months from receipt of issue proceeds.
Trident Lifeline announced a minor dilution in its subsidiary, Trident Mediquip Limited (TML), following a private placement of equity shares to other shareholders. As a result, Trident Lifeline's holding in TML has reduced from 59.67% to 58.23%, maintaining majority subsidiary control. TML operates in the medical device sector and generated a turnover of Rs 27.31 Cr in FY26, up from Rs 21.29 Cr in FY25. This turnover represents approximately 15% of Trident Lifeline's consolidated FY26 revenue of Rs 178.32 Cr.
- Shareholding in subsidiary Trident Mediquip Limited diluted from 59.67% to 58.23%
- Trident Mediquip reported a turnover of Rs 27.31 Cr in FY 2025-26
- Trident Mediquip's prior revenues stood at Rs 21.29 Cr (FY25) and Rs 20.58 Cr (FY24)
- Paid-up share capital of Trident Mediquip stands at Rs 10,24,69,800 across 1,02,46,980 equity shares of Rs 10 each
Trident Lifeline announced its participation in CPHI Milan 2026, held from October 6 to 8 at Fiera Milano, Italy. The event served as a platform to showcase the company's finished dose pharmaceutical products and connect with global buyers in targeted regulated markets. No commercial orders, financial commitments, or formal business tie-ups were quantified in the filing. The company reported TTM revenue of Rs 188 Cr and aims to expand through international product registrations.
- Participated in CPHI Milan 2026 held from October 6 to October 8, 2026, at Fiera Milano, Italy
- Showcased formulation portfolio across pharmaceuticals, nutraceuticals, injectables, and medical devices
- Targeting regulated pharma markets; no specific deal values or confirmed contract figures disclosed
- Company operates on TTM revenue of Rs 188 Cr and FY26 PAT of Rs 26.42 Cr
Trident Lifeline has issued an EGM notice for October 27, 2026, to seek shareholder approval for raising ₹41.14 crore through a preferential issue of equity shares. The company plans to issue up to 12,22,200 equity shares to 23 non-promoter entities at an issue price of ₹336.60 per share (including a premium of ₹326.60). The proposed fundraise equals approximately 11.3% of the company's current market cap of ₹363 crore and about 41.6% of its net worth (₹99 crore). Additionally, the company is seeking an amendment to its Articles of Association to enable the issuance of convertible securities.
- Proposed preferential issuance of up to 12,22,200 equity shares aggregating ₹41,13,92,520 (₹41.14 crore)
- Issue price set at ₹336.60 per share (including premium of ₹326.60), a premium to the current market price of ₹303.6
- Shares offered across 23 public/non-promoter allottees, with India Equity Fund 1 being the largest (3,04,200 shares)
- EGM scheduled for October 27, 2026, with remote e-voting cut-off on October 20, 2026
Trident Lifeline's board has approved a preferential allotment of equity shares and convertible warrants to raise up to ₹57.98 crore at an issue price of ₹336.60 per unit. The issuance comprises 12,22,200 equity shares raising ₹41.14 crore from non-promoters, and 5,00,400 fully convertible warrants raising up to ₹16.84 crore from promoters and non-promoters. The issue price of ₹336.60 represents an approximate 10.9% premium over the current market price of ₹303.60. An Extra-Ordinary General Meeting (EGM) is scheduled for October 27, 2026, to seek shareholder approval.
- Approved issuance of 12,22,200 equity shares at ₹336.60 each, aggregating to ₹41,13,92,520 to non-promoter public investors
- Approved issuance of up to 5,00,400 fully convertible warrants at ₹336.60 each, aggregating to ₹16,84,34,640 (25% upfront, 75% within 18 months)
- Issue price of ₹336.60 per unit reflects a premium over the current share price of ₹303.60
- Total capital raise of ₹57.98 Cr represents ~17% of the company's current market cap of ₹341 Cr and ~58.6% of net worth
- Post-issue promoter holding is projected to reduce from 62.46% to 56.35% on a fully diluted basis
Trident Lifeline's board has approved a preferential allotment of equity shares and convertible warrants to raise up to ₹57.98 crore at an issue price of ₹336.60 per unit. The issuance comprises 12,22,200 equity shares raising ₹41.14 crore from non-promoters, and 5,00,400 fully convertible warrants raising up to ₹16.84 crore from promoters and non-promoters. The issue price of ₹336.60 represents an approximate 10.9% premium over the current market price of ₹303.60. An Extra-Ordinary General Meeting (EGM) is scheduled for October 27, 2026, to seek shareholder approval.
- Approved issuance of 12,22,200 equity shares at ₹336.60 each, aggregating to ₹41,13,92,520 to non-promoter public investors
- Approved issuance of up to 5,00,400 fully convertible warrants at ₹336.60 each, aggregating to ₹16,84,34,640 (25% upfront, 75% within 18 months)
- Issue price of ₹336.60 per unit reflects a premium over the current share price of ₹303.60
- Total capital raise of ₹57.98 Cr represents ~17% of the company's current market cap of ₹341 Cr and ~58.6% of net worth
- Post-issue promoter holding is projected to reduce from 62.46% to 56.35% on a fully diluted basis
Trident Lifeline's board has approved a preferential allotment of equity shares and convertible warrants to raise up to ₹57.98 crore at an issue price of ₹336.60 per unit. The issuance comprises 12,22,200 equity shares raising ₹41.14 crore from non-promoters, and 5,00,400 fully convertible warrants raising up to ₹16.84 crore from promoters and non-promoters. The issue price of ₹336.60 represents an approximate 10.9% premium over the current market price of ₹303.60. An Extra-Ordinary General Meeting (EGM) is scheduled for October 27, 2026, to seek shareholder approval.
- Approved issuance of 12,22,200 equity shares at ₹336.60 each, aggregating to ₹41,13,92,520 to non-promoter public investors
- Approved issuance of up to 5,00,400 fully convertible warrants at ₹336.60 each, aggregating to ₹16,84,34,640 (25% upfront, 75% within 18 months)
- Issue price of ₹336.60 per unit reflects a premium over the current share price of ₹303.60
- Total capital raise of ₹57.98 Cr represents ~17% of the company's current market cap of ₹341 Cr and ~58.6% of net worth
- Post-issue promoter holding is projected to reduce from 62.46% to 56.35% on a fully diluted basis
Trident Lifeline Limited has acquired an additional 1.00% equity stake in its subsidiary, Trident Mediquip Limited (TML), for a cash consideration of approximately ₹95.40 lakh. This transaction raises Trident Lifeline's total shareholding in TML from 58.67% to 59.67%. TML operates in the medical device sector and recorded a turnover of ₹27.31 crore in FY 2025-26, up from ₹21.29 crore in FY 2024-25. The transaction is conducted at arm's length as a related-party acquisition involving common directors and promoters.
- Acquired an additional 1.00% equity stake in subsidiary Trident Mediquip Limited (TML)
- Holding increased from 58.67% to 59.67%
- Total cash consideration paid is approximately ₹95.40 lakh
- Target entity TML reported FY 2025-26 turnover of ₹27.31 crore (up from ₹21.29 crore in FY 2024-25)
Trident Lifeline Limited has revised the book closure dates and cut-off date for its upcoming 13th Annual General Meeting (AGM). The revised book closure is set from Sunday, September 20, 2026, to Saturday, September 26, 2026 (both days inclusive). The revised cut-off date for remote e-voting and voting during the AGM is now Saturday, September 19, 2026, shifting by one day from the previously announced September 18, 2026. All other terms from the board meeting held on August 26, 2026, remain unchanged.
- Revised Book Closure start date to Sunday, September 20, 2026 (closing on September 26, 2026)
- Revised Cut-off date for remote e-voting to Saturday, September 19, 2026 (earlier September 18, 2026)
- Meeting purpose: 13th Annual General Meeting (AGM)
- Continuation of the prior intimation dated August 26, 2026
Trident Lifeline Ltd has approved the allotment of 24,000 equity shares of face value ₹10 each at an exercise price of ₹266 per share upon conversion of warrants. The company received the remaining 75% exercise consideration amounting to ₹47.88 lakh from allottee Ashish Anandsingh Bafna. Following the allotment, the company's paid-up equity share capital increased marginally to ₹11.96 crore divided into 1,19,57,000 equity shares.
- Allotted 24,000 equity shares upon conversion of equal number of warrants
- Conversion executed at an issue price of ₹266 per share (including ₹256 premium)
- Received balance 75% payment aggregating to ₹47,88,000
- Paid-up share capital increased to ₹11,95,70,000 (1,19,57,000 shares)
Trident Lifeline Ltd has approved the allotment of 24,000 equity shares of face value ₹10 each upon the conversion of an equal number of warrants to a non-promoter/investor. The company received the remaining 75% exercise price of ₹199.50 per warrant, aggregating to ₹47,88,000. Total issue price per share was ₹266 (including ₹256 premium), as originally fixed in June 2025. Following this allotment, the company's paid-up equity share capital increases marginally to ₹11.96 crore comprising 1,19,57,000 shares.
- Allotment of 24,000 equity shares upon conversion of 24,000 preferential warrants
- Received balance 75% exercise amount of ₹47,88,000 (₹199.50 per warrant)
- Issue price fixed at ₹266 per share (face value ₹10 + premium of ₹256)
- Paid-up equity capital increased to ₹11,95,70,000 (1,19,57,000 equity shares)
Trident Lifeline Ltd has been selected by the Pharmaceuticals Export Promotion Council of India (PHARMEXCIL) for the 'Outstanding Contribution to India's Pharmaceutical Exports' award for the year 2024-25. The award will be presented during the 12th Edition of International Pharmaceutical Exhibition on September 7, 2026, in New Delhi. While validating the company's export positioning, this announcement is recognitory and does not bring direct financial or order inflows.
- Awarded 'Outstanding Contribution to India's Pharmaceutical Exports' by PHARMEXCIL for 2024-25
- Presentation scheduled for 7 September 2026 at 5:00 PM at Bharat Mandapam, New Delhi
- Conferred during the 12th Edition of International Pharmaceutical Exhibition
Trident Lifeline Limited has announced that its 13th Annual General Meeting (AGM) will be held on Saturday, September 26, 2026, via Video Conferencing. The company's Register of Members and Share Transfer Books will be closed from September 19 to September 26, 2026. The cut-off date for remote e-voting has been fixed as Friday, September 18, 2026. The board has also recommended the reappointment of Mr. Hardik Jigishkumar Desai, Director retiring by rotation, subject to shareholder approval.
- 13th Annual General Meeting scheduled for September 26, 2026, at 4:00 PM via Video Conferencing
- Share transfer books and register of members closed from September 19, 2026, to September 26, 2026
- Cut-off date for remote e-voting and e-voting during AGM set as September 18, 2026
- Recommended reappointment of director Mr. Hardik Jigishkumar Desai (DIN: 01358227) who retires by rotation
Trident Lifeline Limited has announced that its 13th Annual General Meeting (AGM) will be held on Saturday, September 26, 2026, via Video Conferencing. The cut-off date to determine shareholder eligibility for remote e-voting is set for Friday, September 18, 2026. The company's register of members and share transfer books will remain closed from September 19 to September 26, 2026. Additionally, the Board recommended the reappointment of Mr. Hardik Jigishkumar Desai, who retires by rotation.
- 13th AGM scheduled for Saturday, September 26, 2026, at 4:00 p.m. IST via VC/OAVM
- Cut-off date for remote e-voting fixed as Friday, September 18, 2026
- Book closure period set from September 19, 2026, to September 26, 2026 (both days inclusive)
- Recommended reappointment of Director Mr. Hardik Jigishkumar Desai (DIN: 01358227), who retires by rotation
Financial Performance
Revenue Growth by Segment
Tablets and capsules (56% of revenue), Toothpaste/mouthwash/ointments (36%), Syrups (5%), Suspensions (3%). Revenue grew 53% YoY in H1FY26 to INR 47.90 Cr.
Geographic Revenue Split
Exports (68%), Domestic (32%). Continent split: Asia (44%), South America (38%), Africa (17%), ROW (1%).
Profitability Margins
PAT margin stood at 17.5% in H1FY26 (INR 8.41 Cr). FY25 PAT margin was 18.4% (INR 13.05 Cr).
EBITDA Margin
EBITDA margin was 27% in H1FY26, a decrease of 319 BPS from 30% in H1FY25. Q2FY26 margin was 26%.
Capital Expenditure
Non-current assets increased by INR 8.39 Cr, from INR 20.26 Cr in FY24 to INR 28.65 Cr in FY25, reflecting investments in manufacturing and registrations.
Credit Rating & Borrowing
Interest costs rose 59% YoY to INR 74.36 Lakh in H1FY26 due to elevated borrowing for business investments. Credit rating not disclosed.
Operational Drivers
Raw Materials
Generic categories include Raw Materials and Packaging Materials. Specific chemical names not disclosed.
Key Suppliers
Not specifically disclosed; company uses a hybrid model of own and third-party contract manufacturers.
Capacity Expansion
Current monthly capacity: Tablets (120M), Capsules (120M), Dry Powder (3M), Ointments (3M), Liquid (3M), Injectables (10M).
Raw Material Costs
Total operating expenses were INR 34.95 Cr in H1FY26, representing 73% of total revenue.
Manufacturing Efficiency
Not disclosed; company focuses on superior ROCEs through backloaded investment benefits as business scales.
Strategic Growth
Expected Growth Rate
53%
Growth Strategy
Achieving growth through 300-400 new product registrations annually, focusing on molecules going off-patent, and expanding the sales team with dedicated country heads in 44 countries.
Products & Services
Pharmaceutical formulations including Tablets, Capsules, Dry Powder Bottles, Ointments, Liquid Bottles, Injectables, Gels, Mouthwash, and Syrups.
Brand Portfolio
Over 61 registered brands (specific names not listed).
New Products/Services
Adding 300-400 registrations per year; focus on molecules going off-patent in developed markets to capture superior margins.
Market Expansion
Clustered growth strategy targeting at least 50-100 registrations in each key market across South America, Africa, and Asia.
Strategic Alliances
Strategic tie-ups with third-party contract manufacturers and global B2B channel partners/merchant exporters.
External Factors
Industry Trends
Pharma formulations export market is growing; Trident is positioning for future growth by focusing on molecules going off-patent in developed markets.
Competitive Landscape
Hybrid manufacturing model allows for flexible scaling against competitors; focus on branded sales to establish brand recall.
Competitive Moat
Durable advantage through a portfolio of 1,061 registered products and 2,384 in pipeline; the 1.5-3 year registration gestation period acts as a high entry barrier.
Macro Economic Sensitivity
Sensitivity to healthcare spending and regulatory approvals in emerging markets.
Consumer Behavior
Increasing demand for affordable, high-quality pharmaceutical formulations in African and Latin American markets.
Geopolitical Risks
68% export revenue is sensitive to political and regulatory changes in key markets like Venezuela and Ghana.
Regulatory & Governance
Industry Regulations
Requires WHO-GMP certification and facility/product registrations with foreign healthcare authorities for export operations.
Taxation Policy Impact
Effective tax rate of approximately 24.2% based on H1FY26 PBT of INR 11.10 Cr and PAT of INR 8.41 Cr.
Risk Analysis
Key Uncertainties
Gestation period for registrations (1.5-3 years) and dependency on third-party manufacturers for the hybrid model.
Geographic Concentration Risk
61% of total product registrations are concentrated in four countries: Venezuela, Ghana, Cambodia, and Kenya.
Third Party Dependencies
Significant reliance on contract manufacturing sites to fulfill future demand for tablets and capsules.
Technology Obsolescence Risk
Not disclosed; company is currently focused on generic formulations and off-patent molecules.
Credit & Counterparty Risk
Trade receivables stood at INR 20.40 Cr in FY25, representing 28.7% of total revenue.
